<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377947</url>
  </required_header>
  <id_info>
    <org_study_id>EPIDJ001</org_study_id>
    <secondary_id>REF/2014/11/007981</secondary_id>
    <nct_id>NCT02377947</nct_id>
  </id_info>
  <brief_title>A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) [The RETRO Study]</brief_title>
  <official_title>A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) [The RETRO Study]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective study in adult patients with cirrhosis and grade 3 or 4 HE (West
      Haven Criteria) to evaluate the effectiveness and safety of lactulose retention enema in the
      treatment of deep grade HE (West Haven Criteria). The study will be conducted retrospectively
      in a multi center of a multispecialty tertiary care hospital in India, in which lactulose
      retention enema is the mainstay of management of cirrhotic patients with grade 3 or 4 HE
      (West Haven criteria). Dosing of lactulose retention enema in this study will be done
      according to the dosing described for rectal administration of lactulose (India): 300ml of
      lactulose mixed with 700ml of potable water to be used as a retention enema; the enema is to
      be retained for 30-60 minutes and repeated every 4-6 hours until the patient is able to take
      oral medication. This treatment regime is also the standard protocol of management of deep
      grade HE (West Haven criteria) in the study centers. The standard treatment protocol of deep
      grade HE (West Haven criteria) of the study centers will also ensure that all known
      contraindications of lactulose will be respected before administration of lactulose retention
      enema to the study patients. The retrospective hospital records of the patient population of
      interest within the past 6 months will be identified, and these records will be used to
      collect data required for analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data to be collected:

      Data that would be collected for the study as part of retrospective chart review:

        1. Patient demographics: age, gender, weight

        2. Medical history

        3. Etiology of cirrhosis (alcohol abuse, hepatitis, autoimmune, cryptogenic, other)

        4. Diagnosis of cirrhosis

        5. History of previous HE (if yes, the number of episodes in the past)

        6. Grade of HE (as per the West-Haven criteria) at admission, 24 hrs and 48 hours post
           treatment with lactulose

        7. Precipitating factor(s) of HE (Dehydration, GI bleeding, protein overload, constipation,
           infection, others)

        8. Dose and duration of lactulose enema

        9. Treatment given for precipitating factors

       10. Laboratory data on haemoglobin, platelet, bilirubin, albumin, aspartate aminotransferase
           (AST), alanine aminotransferase (ALT), urea, creatinine, sodium, potassium, and blood
           ammonia

       11. Complete reversal of deep-grade HE (&lt; Grade 2 as per West-Haven criteria) (yes/no)

       12. Time to complete reversal of deep-grade HE

       13. Number of days in hospital

       14. Adverse drug reaction experienced by the patient

       15. Complications experienced by the patient

       16. Other pharmacovigilance relevant information (OPRI)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Reversal</measure>
    <time_frame>24 hrs</time_frame>
    <description>Percentage of patients with complete reversal of deep-grade (Grade 3 and 4 West-Haven Criteria) Hepatic Encephalopathy after administration of lactulose retention enema</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Reversal</measure>
    <time_frame>48 hrs</time_frame>
    <description>Percentage of patients with complete reversal of deep-grade (Grade 3 and 4 West-Haven Criteria) Hepatic Encephalopathy after administration of lactulose retention enema</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatic Encephalopathy (HE) Grade Shift at 24 and 48 Hours</measure>
    <time_frame>HE Grade shift at 24 hrs and HE Grade shift at 48 hrs</time_frame>
    <description>Grade shift at 24 and 48 hours - from baseline to 24 and 48 hours post administration of lactulose retention enema.
Complete reversal of deep grade HE is defined as subjects having HE grade=&lt;grade 2 as per West-Haven criteria where grade 0 is Normal, Grade 1 is Mild lack of awareness, Grade 2 is Lethargic, Grade 3 is Somnolent but arousable and Grade 4 is Coma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Complete Reversal</measure>
    <time_frame>up to 48 hrs</time_frame>
    <description>Time to complete reversal of deep-grade (Grade 3 and 4 West-Haven Criteria) HE after administration of lactulose retention enema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>within 48 hrs</time_frame>
    <description>Mortality in patients treated with lactulose retention enema</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety of Lactulose Retention Enema (Number of Adverse Drug Reactions &amp; Complications).</measure>
    <time_frame>Chart Review of Events over 48 Hour Period</time_frame>
    <description>Safety of Lactulose retention enema (number of adverse drug reactions &amp; complications). Complications pertinent to lactulose retention enema are in reference to potential adverse effects associated with the use of rectal device associated with the application of the lactulose retention enema kit.</description>
  </other_outcome>
  <other_outcome>
    <measure>Reduction in Blood Ammonia Level</measure>
    <time_frame>reported at 48 hrs</time_frame>
    <description>Change from baseline was calculated at the end of treatment by using following formula wherever applicable:
Change from baseline = Blood ammonia level at the end of treatment - Blood ammonia level at baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of Hospital Stay</measure>
    <time_frame>upto 30 days of hospital admission</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Patients with cirrhosis (grade 3 &amp; 4 per west haven cr.)</arm_group_label>
    <description>Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Retrospective study - data charts of the cirrhotic patients having grade III and IV and who
        were administered lactulose enema will be reviewed.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 18 and 65 years of either gender.

          -  Patients admitted to the hospital with liver cirrhosis and grade 3 or grade 4 (West
             Haven Criteria) HE

          -  Patients treated with lactulose retention enema within 48 hours of onset of grade 3 or
             4 (West Haven Criteria) HE

        Exclusion Criteria:

          -  Patients treated with agents other than lactulose retention enema for grade 3 or 4
             (West Haven Criteria) HE.

          -  Patients who had significant concomitant diseases that could impair or contribute to
             the impairment of consciousness

          -  Patients who had a major neuropsychiatric illness

          -  Patients who had a contraindication to lactulose, including Hypersensitivity to the
             active substance or to any of the ingredients; Galactosaemia; Gastrointestinal
             obstruction, digestive perforation or risk of digestive perforation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dyotona Roy-Sengupta</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medanta Hospital</name>
      <address>
        <city>Gurgaon</city>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ORG-000333</name>
      <address>
        <city>Gurgaon</city>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Ganga Ram Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <results_first_submitted>September 18, 2017</results_first_submitted>
  <results_first_submitted_qc>February 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2020</results_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lactulose Retention Enema</keyword>
  <keyword>Hepatic Encephalopathy, Grade 3 or 4 West Haven Criteria</keyword>
  <keyword>The Retro Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients With Cirrhosis (Grade 3 &amp; 4 Per West Haven cr.)</title>
          <description>Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients With Cirrhosis (Grade 3 &amp; 4 Per West Haven cr.)</title>
          <description>Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.38" spread="10.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Reversal</title>
        <description>Percentage of patients with complete reversal of deep-grade (Grade 3 and 4 West-Haven Criteria) Hepatic Encephalopathy after administration of lactulose retention enema</description>
        <time_frame>24 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Cirrhosis (Grade 3 &amp; 4 Per West Haven cr.)</title>
            <description>Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Reversal</title>
          <description>Percentage of patients with complete reversal of deep-grade (Grade 3 and 4 West-Haven Criteria) Hepatic Encephalopathy after administration of lactulose retention enema</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="66.3" upper_limit="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Complete Reversal</title>
        <description>Percentage of patients with complete reversal of deep-grade (Grade 3 and 4 West-Haven Criteria) Hepatic Encephalopathy after administration of lactulose retention enema</description>
        <time_frame>48 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Cirrhosis (Grade 3 &amp; 4 Per West Haven cr.)</title>
            <description>Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Reversal</title>
          <description>Percentage of patients with complete reversal of deep-grade (Grade 3 and 4 West-Haven Criteria) Hepatic Encephalopathy after administration of lactulose retention enema</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="78.2" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatic Encephalopathy (HE) Grade Shift at 24 and 48 Hours</title>
        <description>Grade shift at 24 and 48 hours - from baseline to 24 and 48 hours post administration of lactulose retention enema.
Complete reversal of deep grade HE is defined as subjects having HE grade=&lt;grade 2 as per West-Haven criteria where grade 0 is Normal, Grade 1 is Mild lack of awareness, Grade 2 is Lethargic, Grade 3 is Somnolent but arousable and Grade 4 is Coma</description>
        <time_frame>HE Grade shift at 24 hrs and HE Grade shift at 48 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Cirrhosis (Grade 3 &amp; 4 Per West Haven cr.)</title>
            <description>Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Encephalopathy (HE) Grade Shift at 24 and 48 Hours</title>
          <description>Grade shift at 24 and 48 hours - from baseline to 24 and 48 hours post administration of lactulose retention enema.
Complete reversal of deep grade HE is defined as subjects having HE grade=&lt;grade 2 as per West-Haven criteria where grade 0 is Normal, Grade 1 is Mild lack of awareness, Grade 2 is Lethargic, Grade 3 is Somnolent but arousable and Grade 4 is Coma</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>shift from HE Grade 3 to &lt;2 after 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>shift from HE Grade 4 to &lt;2 after 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>shift from HE Grade 3 to &lt;2 after 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>shift from HE Grade 4 to &lt;2 after 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Complete Reversal</title>
        <description>Time to complete reversal of deep-grade (Grade 3 and 4 West-Haven Criteria) HE after administration of lactulose retention enema</description>
        <time_frame>up to 48 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Cirrhosis (Grade 3 &amp; 4 Per West Haven cr.)</title>
            <description>Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Complete Reversal</title>
          <description>Time to complete reversal of deep-grade (Grade 3 and 4 West-Haven Criteria) HE after administration of lactulose retention enema</description>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.39" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>Mortality in patients treated with lactulose retention enema</description>
        <time_frame>within 48 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Cirrhosis (Grade 3 &amp; 4 Per West Haven cr.)</title>
            <description>Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Mortality in patients treated with lactulose retention enema</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Safety of Lactulose Retention Enema (Number of Adverse Drug Reactions &amp; Complications).</title>
        <description>Safety of Lactulose retention enema (number of adverse drug reactions &amp; complications). Complications pertinent to lactulose retention enema are in reference to potential adverse effects associated with the use of rectal device associated with the application of the lactulose retention enema kit.</description>
        <time_frame>Chart Review of Events over 48 Hour Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Cirrhosis (Grade 3 &amp; 4 Per West Haven cr.)</title>
            <description>Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Lactulose Retention Enema (Number of Adverse Drug Reactions &amp; Complications).</title>
          <description>Safety of Lactulose retention enema (number of adverse drug reactions &amp; complications). Complications pertinent to lactulose retention enema are in reference to potential adverse effects associated with the use of rectal device associated with the application of the lactulose retention enema kit.</description>
          <units>number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Reduction in Blood Ammonia Level</title>
        <description>Change from baseline was calculated at the end of treatment by using following formula wherever applicable:
Change from baseline = Blood ammonia level at the end of treatment - Blood ammonia level at baseline</description>
        <time_frame>reported at 48 hrs</time_frame>
        <population>The ammonia levels were available at baseline for 28 patients where as the last observed blood ammonia level after administration of lactulose enema was available for 4 patients. Thus the change from baseline was calculated for 4 patients. The Change value = Visit value - Baseline Value</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Cirrhosis (Grade 3 &amp; 4 Per West Haven cr.)</title>
            <description>Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Blood Ammonia Level</title>
          <description>Change from baseline was calculated at the end of treatment by using following formula wherever applicable:
Change from baseline = Blood ammonia level at the end of treatment - Blood ammonia level at baseline</description>
          <population>The ammonia levels were available at baseline for 28 patients where as the last observed blood ammonia level after administration of lactulose enema was available for 4 patients. Thus the change from baseline was calculated for 4 patients. The Change value = Visit value - Baseline Value</population>
          <units>Mcg/DL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.6" spread="11.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Duration of Hospital Stay</title>
        <time_frame>upto 30 days of hospital admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Cirrhosis (Grade 3 &amp; 4 Per West Haven cr.)</title>
            <description>Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Hospital Stay</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229.4" spread="147.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>As this study was a retrospective chart review of 50 patients who were treated with lactulose enema, only (S)ADRs and complications were collected. Thus, the total of participants at risk were 50 for ADRs and complications. Complications pertinent to lactulose retention enema are in reference to potential adverse effects associated with the use of rectal device associated with the application of the lactulose retention enema kit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Patients With Cirrhosis (Grade 3 &amp; 4 Per West Haven cr.)</title>
          <description>Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea and Abdominal discomfort</sub_title>
                <description>Only ADRs and complications were collected. Observed non serious ADRs are either considered to be sufficiently described in the section on undesirable effects in local label and/or associated with the method of administration as a retention enema</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Abdominal fullness and discomfort</sub_title>
                <description>Only ADRs and complications were collected. Observed non serious ADRs are either considered to be sufficiently described in the section on undesirable effects in local label and/or associated with the method of administration as a retention enema</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Mild rectal bleed</sub_title>
                <description>Only ADRs and complications were collected. Observed non serious ADRs are either considered to be sufficiently described in the section on undesirable effects in local label and/or associated with the method of administration as a retention enema</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Shubhangi Desai</name_or_title>
      <organization>Abbott</organization>
      <phone>+91 22 7175 7408</phone>
      <email>shubhangi.desai@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

